This trial is conducted in Asia. The aim of this trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of insulin degludec/insulin aspart in healthy Chinese subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
24
A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
Novo Nordisk Investigational Site
Beijing, China
Area under the serum insulin degludec concentration-time curve
Time frame: From 0 to 120 hours after single dose
Area under the serum insulin aspart concentration-time curve
Time frame: From 0 to 12 hours after single dose
Maximum observed serum insulin degludec concentration
Time frame: After single dose (within 0 to 120 hours after dosing)
Maximum observed serum insulin aspart concentration
Time frame: After single dose (within 0 to 12 hours after dosing)
Time to maximum observed serum insulin degludec concentration
Time frame: After single dose (within 0 to 120 hours after dosing)
Time to maximum observed serum insulin aspart concentration
Time frame: After single dose (within 0 to 12 hours after dosing)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.